ScreenerHero

OGI Organigram Global Inc.

TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · organigram.ca
1.340CAD-1.47%Mkt Cap: 137.60M $P/E: 2.23

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vap…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap137.60M USD
Enterprise Value205.96M USD
Revenue (TTM)225.16M USD
Gross Profit65.70M USD
Net Income (TTM)-18.03M USD
Revenue/Share2.27 CAD
Last Price1.340 CAD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees1.1K
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA68620P1018
Valuation
P/E (Trailing)2.23
P/E (Forward)41.26
PEG—
EV/EBITDA17.22
EV/Revenue0.91
P/S0.62
P/B0.39
EPS (TTM)0.60
EPS (Forward)0.03
52W Range
1.1958% of range3.090
52W High3.090 CAD
52W Low1.195 CAD
Profitability
Gross Margin34.81%
Oper. Margin5.04%
EBITDA Margin5.31%
Profit Margin-9.55%
ROE-7.09%
ROA-4.40%
Growth
Revenue Growth49.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.53M USD
CapEx (TTM)12.42M USD
FCF Margin-0.40%
FCF Yield-0.66%
Net Debt14.55M USD
Net Debt/EBITDA1.22
Balance Sheet
Debt/Equity0.03
Current Ratio2.61
Quick Ratio0.94
Book Value/Sh3.44 CAD
Cash/Share0.08 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateJul 7, 2023
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.120 CAD
Upside (mean)+132.8%
Target Range1.850 CAD – 4.000 CAD
1.850+132.8% to mean4.000
# Analysts5
Ownership
Shares Out.141.01M
Float97.33M
Insiders31.06%
Institutions6.54%
Short Interest
Short Ratio9.0d
Short % Out.0.79%
Shares Short1.14M
Short (prev mo.)2.21M
Technical
SMA 501.529 (-12.4%)
SMA 2001.776 (-24.5%)
Beta1.91
S&P 52W Chg14.58%
Avg Vol (30d)150.76K
Avg Vol (10d)117.64K
Technical Indicators
RSI (14)35.5
MACD-0.0342
MACD Signal-0.0115
MACD Hist.-0.0227
BB Upper1.629 CAD
BB Middle1.488 CAD
BB Lower1.346 CAD
BB Width19.07%
ATR (14)0.0630 CAD
Vol Ratio (20d)1.42x